These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814 [TBL] [Abstract][Full Text] [Related]
3. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209 [TBL] [Abstract][Full Text] [Related]
4. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Faber MS; Fuhr U Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794 [TBL] [Abstract][Full Text] [Related]
5. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Denaro CP; Wilson M; Jacob P; Benowitz NL Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991 [TBL] [Abstract][Full Text] [Related]
6. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Pavanello S; Simioli P; Lupi S; Gregorio P; Clonfero E Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):998-1003. PubMed ID: 12376499 [TBL] [Abstract][Full Text] [Related]
7. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Tang BK; Zhou Y; Kadar D; Kalow W Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691 [TBL] [Abstract][Full Text] [Related]
8. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Benowitz NL; Peng M; Jacob P Clin Pharmacol Ther; 2003 Nov; 74(5):468-74. PubMed ID: 14586387 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Perera V; Gross AS; Xu H; McLachlan AJ J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488 [TBL] [Abstract][Full Text] [Related]
10. Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking. Lee CH; Wu DC; Lee JM; Wu IC; Goan YG; Kao EL; Huang HL; Chan TF; Chou SH; Chou YP; Lee CY; Chen PS; Ho CK; He J; Wu MT Eur J Cancer; 2007 May; 43(7):1188-99. PubMed ID: 17383866 [TBL] [Abstract][Full Text] [Related]
11. Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Pavanello S; Pulliero A; Lupi S; Gregorio P; Clonfero E Mutat Res; 2005 Nov; 587(1-2):59-66. PubMed ID: 16188490 [TBL] [Abstract][Full Text] [Related]
12. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Rasmussen BB; Brøsen K Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579 [TBL] [Abstract][Full Text] [Related]
13. Effects of rutaecarpine on the metabolism and urinary excretion of caffeine in rats. Noh K; Seo YM; Lee SK; Bista SR; Kang MJ; Jahng Y; Kim E; Kang W; Jeong TC Arch Pharm Res; 2011 Jan; 34(1):119-25. PubMed ID: 21468923 [TBL] [Abstract][Full Text] [Related]
14. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. Danie WA; Syrek M; Ryłko Z; Wójcikowski J Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081 [TBL] [Abstract][Full Text] [Related]
15. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers. Chen Y; Tu JH; He YJ; Zhang W; Wang G; Tan ZR; Zhou G; Fan L; Zhou HH Xenobiotica; 2009 Jul; 39(7):508-13. PubMed ID: 19534587 [TBL] [Abstract][Full Text] [Related]
17. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Faber MS; Jetter A; Fuhr U Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905 [TBL] [Abstract][Full Text] [Related]
18. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Chung WG; Kang JH; Park CS; Cho MH; Cha YN Clin Pharmacol Ther; 2000 Mar; 67(3):258-66. PubMed ID: 10741629 [TBL] [Abstract][Full Text] [Related]
19. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Dobrinas M; Cornuz J; Oneda B; Kohler Serra M; Puhl M; Eap CB Clin Pharmacol Ther; 2011 Jul; 90(1):117-25. PubMed ID: 21593735 [TBL] [Abstract][Full Text] [Related]
20. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]